Dr. Bhuvin M. Buddhdev, MD
Pulmonology (Pulmonary Disease Physician)
500 W Thomas Rd Ste 500
Phoenix, AZ 85013
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 247
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
AZ license 55589 -
Critical Care Medicine (Internal Medicine) Physician
AZ license 55589
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital and Medical Center Phoenix, AZ
- Yavapai Regional Medical Center Prescott, AZ
- Tri-State Memorial Hospital Clarkston, WA
Medical groups
- Sjhmc Physician Services (646 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 247
- Services billed
- 1,123
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 248 | 178 |
| X-ray of chest, 2 views | 192 | 130 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 183 | 46 |
| Critical care, first 30-74 minutes | 108 | 34 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 48 | 38 |
| Hospital discharge day management, more than 30 minutes | 33 | 29 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 32 | 27 |
| Biopsy of lobe of lung using an endoscope, each additional lobe | 32 | 27 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 27 | 25 |
| Aspiration of initial secretion of lung airway using an endoscope | 23 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Phoenix, AZ | 233 |
| Montelukast Sodium Other prescribers in Phoenix, AZ | 159 |
| Azithromycin Other prescribers in Phoenix, AZ | 157 |
| Itraconazole | 111 |
| Omeprazole Other prescribers in Phoenix, AZ | 111 |
| Valganciclovir Hcl | 103 |
| Acyclovir Other prescribers in Phoenix, AZ | 95 |
| Alendronate Sodium Other prescribers in Phoenix, AZ | 78 |
| Eliquis (apixaban) Other prescribers in Phoenix, AZ | 77 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Phoenix, AZ | 77 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 83 payments worth $14,114 in total to this clinician.
| United Therapeutics Corporation | $11,100 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $1,671 |
| AbbVie Inc. | $272 |
| Bayer HealthCare Pharmaceuticals Inc. | $200 |
| Insmed, Inc. | $165 |
| Abiomed | $140 |
| Merck Sharp & Dohme LLC | $127 |
| Johnson & Johnson Health Care Systems Inc. | $107 |
| Consulting Fee | $9,265 |
|---|---|
| Food and Beverage | $4,037 |
| Travel and Lodging | $812 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| United Therapeutics Corporation Oct 3, 2025 | Consulting Fee TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $6,550 |
| United Therapeutics Corporation Oct 18, 2025 | Consulting Fee | $2,020 |
| Actelion Pharmaceuticals US, Inc. Dec 12, 2025 | Consulting Fee UPTRAVI · Cardiology | $495 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX · in-kind | $255 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX · in-kind | $234 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
| United Therapeutics Corporation Oct 18, 2025 | Travel and Lodging travel to Chicago, IL | $127 |
| United Therapeutics Corporation Oct 3, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $64.94 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $54.70 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $48.10 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Dec 12, 2025 | Consulting Fee UPTRAVI · Cardiology | $495 |
| United Therapeutics Corporation Oct 18, 2025 | Consulting Fee | $2,020 |
| United Therapeutics Corporation Oct 18, 2025 | Travel and Lodging travel to Chicago, IL | $127 |
| United Therapeutics Corporation Oct 18, 2025 | Travel and Lodging travel to Chicago, IL | $20.00 |
| United Therapeutics Corporation Oct 3, 2025 | Consulting Fee TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $6,550 |
| United Therapeutics Corporation Oct 3, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $64.94 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX · in-kind | $255 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX · in-kind | $234 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $54.70 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $48.10 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $8.00 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $91,968 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.